Your browser doesn't support javascript.
loading
p140Cap inhibits ß-Catenin in the breast cancer stem cell compartment instructing a protective anti-tumor immune response.
Salemme, Vincenzo; Vedelago, Mauro; Sarcinella, Alessandro; Moietta, Federico; Piccolantonio, Alessio; Moiso, Enrico; Centonze, Giorgia; Manco, Marta; Guala, Andrea; Lamolinara, Alessia; Angelini, Costanza; Morellato, Alessandro; Natalini, Dora; Calogero, Raffaele; Incarnato, Danny; Oliviero, Salvatore; Conti, Laura; Iezzi, Manuela; Tosoni, Daniela; Bertalot, Giovanni; Freddi, Stefano; Tucci, Francesco A; De Sanctis, Francesco; Frusteri, Cristina; Ugel, Stefano; Bronte, Vincenzo; Cavallo, Federica; Provero, Paolo; Gai, Marta; Taverna, Daniela; Turco, Emilia; Pece, Salvatore; Defilippi, Paola.
Afiliação
  • Salemme V; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
  • Vedelago M; Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy.
  • Sarcinella A; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
  • Moietta F; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
  • Piccolantonio A; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
  • Moiso E; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
  • Centonze G; Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy.
  • Manco M; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
  • Guala A; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
  • Lamolinara A; Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy.
  • Angelini C; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
  • Morellato A; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
  • Natalini D; Immuno-Oncology Laboratory, Center for Advanced Studies and Technology (CAST), Department of Neuroscience, Imaging and Clinical Sciences, G. d'Annunzio University of Chieti-Pescara, Chieti-Pescara, Italy.
  • Calogero R; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
  • Incarnato D; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
  • Oliviero S; Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy.
  • Conti L; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
  • Iezzi M; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
  • Tosoni D; Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy.
  • Bertalot G; Department of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen, Groningen, the Netherlands.
  • Freddi S; Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy.
  • Tucci FA; Department of Life Sciences and Systems Biology, University of Turin, Torino, Italy and IIGM, Candiolo, Italy.
  • De Sanctis F; Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126, Torino, Italy.
  • Frusteri C; Molecular Biotechnology Center (MBC) "Guido Tarone", Via Nizza, 52, 10126, Turin, Italy.
  • Ugel S; Immuno-Oncology Laboratory, Center for Advanced Studies and Technology (CAST), Department of Neuroscience, Imaging and Clinical Sciences, G. d'Annunzio University of Chieti-Pescara, Chieti-Pescara, Italy.
  • Bronte V; European Institute of Oncology IRCCS, 20141, Milan, Italy.
  • Cavallo F; European Institute of Oncology IRCCS, 20141, Milan, Italy.
  • Provero P; European Institute of Oncology IRCCS, 20141, Milan, Italy.
  • Gai M; European Institute of Oncology IRCCS, 20141, Milan, Italy.
  • Taverna D; School of Pathology, University of Milan, Milan, Italy.
  • Turco E; Immunology Section, Department of Medicine, University of Verona, 37134, Verona, Italy.
  • Pece S; Immunology Section, Department of Medicine, University of Verona, 37134, Verona, Italy.
  • Defilippi P; Immunology Section, Department of Medicine, University of Verona, 37134, Verona, Italy.
Nat Commun ; 14(1): 2350, 2023 05 11.
Article em En | MEDLINE | ID: mdl-37169737
ABSTRACT
The p140Cap adaptor protein is a tumor suppressor in breast cancer associated with a favorable prognosis. Here we highlight a function of p140Cap in orchestrating local and systemic tumor-extrinsic events that eventually result in inhibition of the polymorphonuclear myeloid-derived suppressor cell function in creating an immunosuppressive tumor-promoting environment in the primary tumor, and premetastatic niches at distant sites. Integrative transcriptomic and preclinical studies unravel that p140Cap controls an epistatic axis where, through the upstream inhibition of ß-Catenin, it restricts tumorigenicity and self-renewal of tumor-initiating cells limiting the release of the inflammatory cytokine G-CSF, required for polymorphonuclear myeloid-derived suppressor cells to exert their local and systemic tumor conducive function. Mechanistically, p140Cap inhibition of ß-Catenin depends on its ability to localize in and stabilize the ß-Catenin destruction complex, promoting enhanced ß-Catenin inactivation. Clinical studies in women show that low p140Cap expression correlates with reduced presence of tumor-infiltrating lymphocytes and more aggressive tumor types in a large cohort of real-life female breast cancer patients, highlighting the potential of p140Cap as a biomarker for therapeutic intervention targeting the ß-Catenin/ Tumor-initiating cells /G-CSF/ polymorphonuclear myeloid-derived suppressor cell axis to restore an efficient anti-tumor immune response.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article